Search
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is ...
Categories: Stem Cell Factor (KIT) Receptor Inhibitors, P-glycoprotein inhibitorsVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalVibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and ef...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigationalBirch bark extract is rich in triterpenoids with beneficial biological and pharmacological activities. Some of the compounds identified in it include betulin, lupeol, betulinic acid, oleanolic acid, and erythrodiol. Birch bark extract is...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigationalBelumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cl...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates